Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under Estelle® Licensing Agreement
Mithra Receives EUR 1.25 Million Milestone Payment from Fuji Pharma under Estelle® Licensing Agreement Relates…
Social Media
Avicanna Announces Closing of Non-Brokered Private Placement of Debenture Units
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES….
Massive Bio Partners with Asklepieia, BeStrong, and Open Health Alliance in Greece to Enhance Cancer Clinical Trial
NEW YORK–(BUSINESS WIRE)–Massive Bio and Asklepieia will utilize their innovative technologies to provide oncologists and…
SoFi Invest Midyear Investing Report: Optimistic Investors Face Down a Pessimistic Economic Environment
SoFi Invest surveyed over 3,400 Americans on their investing sentiment and habits in the first…
Orchard Therapeutics Strongly Supports Enactment of Newborn Metabolic Screening Act in Illinois, Adding Metachromatic Leukodystrophy to Statewide Panel
BOSTON and LONDON, Aug. 02, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global…
Mirion Announces Second Quarter 2023 Financial Results and Updates Full Year Guidance
Revenues for the second quarter increased 12.2% to $197.2 million, compared to $175.8 million in…
Camping World Holdings, Inc. Reports Second Quarter 2023 Results, Record Used Vehicle Unit Sales, Aggressive RV Dealership Acquisition Pace Continues
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Camping World Holdings, Inc. (NYSE: CWH) (the “Company” or “CWH”), America’s Recreation Dealer,…
Omnicell Announces Second Quarter 2023 Results
Total GAAP revenues of $299 million GAAP net income per diluted share of $0.08 Non-GAAP…
Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St. Jude Children’s Research Hospital for the treatment of High-Risk Neuroblastoma
Press Release Renaissance Pharma launches today and announces the in-licensing of Hu14.18K322A (Hu14.18) from St….
Comcast Business Report Finds Global Cybersecurity Community at a Crossroads as Technology Advancements Accelerate
Cybersecurity Threat Report dissects 23.5 billion attempted cybersecurity attacks against Comcast Business customers – phishing…
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company…
COMPASS Pathways plc to announce second quarter 2023 financial results on August 3, 2023
LONDON, July 31, 2023 (GLOBE NEWSWIRE) — COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company…
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing…
Amarin and Lotus Pharmaceuticals Announce Exclusive Partnership Agreement to Commercialize Vazkepa® (Icosapent Ethyl) in Southeast Asia and South Korea
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing…
Danimer Scientific Announces Release Date for Second Quarter 2023 Results
BAINBRIDGE, Ga.–(BUSINESS WIRE)–Danimer Scientific, Inc. (NYSE: DNMR) (“Danimer” or the “Company”), a leading, next-generation bioplastics…
Aflibercept 8 mg Two-Year Results from Pivotal PHOTON Trial in Diabetic Macular Edema Presented at ASRS
89% and 84% of patients were maintained on ≥12- and ≥16-week dosing intervals, respectively, throughout…
Stratasys Comments on Press Release Issued by 3D Systems
Stratasys Still Waiting for Critical Due Diligence and Regulatory Analysis From 3D Systems MINNEAPOLIS &…
Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
Avicanna is Pleased to Announce the Initial Network of Brands on the MyMedi.ca Platform
The MyMedi.ca medical cannabis care platform is preparing to launch August 1, 2023 The new…
Biogen to Acquire Reata Pharmaceuticals
SKYCLARYS® recently approved in US as the only treatment indicated for patients with Friedreich’s ataxia …